Latest Hemodialysis News
Dialysis providers and facilities should assess and improve infection control practices.
Factors include care practices of physicians, sources of momentum, patient-physician interactions.
In a phase 2 trial, etelcalcitide, a novel peptide agonist of the calcium-sensing receptor, significantly reduced parathyroid hormone levels.
Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients.
Serum total and free testosterone declined in men on hemodialysis who received a 6-month course of the drug for secondary hyperparathyroidism.
Lowest magnesium level was associated with a 74% increased risk of early death compared with mid-range levels.
Primary factor for nonadherence to renal dosing is characteristics of medical institution.
Six-months of supplementation has no impact on epoetin utilization in HD patients with low 25(OH)D.
Researchers observe significant improvements chronic and hemodialysis-induced vascular dysfunction.
Blacks undergoing PD or home HD and Hispanics undergoing PD are less likely than their white counterparts to receive a kidney transplant.
The estimated potential staff time savings totaled 23 hours for an average facility with 70 patients, researchers found.
Rates of death and important non-fatal outcomes between ferumoxytol and iron sucrose or sodium ferric gluconate do not differ significantly.
Prospective study shows no increase in all-cause mortality and cardiovascular events compared with non-use.
More adverse events seen when people undergoing interventional radiology have negative attitude.
Case report describes acyclovir-induced neurotoxicity in patient treated with recommended dose.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)